세계의 G-CSF/PEG-G-CSF 시장 : 업계 동향과 예측(-2030년)

Global G-CSF/ PEG-G-CSF market is projected to register a substantial CAGR of 5.5% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Global G-CSF/PEG-G-CSF Market, By Indication (Neutropenia, Oncology, Chronic and Autoimmune Disease, Blood Disorders, Growth Harmony Deficiency and Others), Dosage (Mono and Combination), Route Of Administration (Intravenous, Subcutaneous), Packaging (Single Use Vials and Pre Filled Syringes), End User (Hospitals and Clinics, Research and Academic Institutes, Ambulatory Surgical Centers and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy and Others), Country (Mexico, Columbia, Brazil, Argentina, Chile, Peru, Ecuador, Rest of LATAM, Germany, U.K., France, Italy, Russia, Netherlands, Spain, Sweden, Poland, Belgium, Switzerland, Denmark, Norway, Finland, Turkey, Rest of Europe, China, Japan, India, Australia, New Zealand, Indonesia, Thailand, Vietnam, Singapore, Philippines, Malaysia, Rest of Asia-Pacific, South Africa, Saudi Arabia, Egypt, Israel, UAE, Kuwait, Oman, and Rest of Middle East and Africa) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the global G-CSF/PEG-G-CSF market are:

Growing incidences of blood cancers and cancer diseases

Increasing cases of febrile neutropenia

Market Players:

The key market players operating in the global G-CSF/PEG-G-CSF market are listed below:

Lupin

Gennova Biopharmaceuticals Limited

Reliance Life Sciences

Intas Pharmaceuticals Ltd.

BIOSIDUS

Kashiv BioSciences, LLC.

STADA Arzneimittel AG

USV Private Limited

Viatris Inc.

Biocon

Fresenius Kabi AG

Hangzhou Jiuyuan Gene Engineering Co., Ltd.

Amgen Inc.

Pfizer Inc.

Sandoz International GmbH

Apotex Inc.

Cadila Pharmaceuticals

Dr. Reddy's Laboratories Ltd.

Amneal Pharmaceuticals LLC.

Coherus BioSciences

Accord Healthcare

NAPP PHARMACEUTICALS LIMITED.

Intas Pharmaceuticals Ltd.

Mundipharma International

Teva Pharmaceutical Industries Ltd.

Spectrum Pharmaceuticals, Inc.

Kyowa Kirin Co., Ltd.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

TABLE OF CONTENTS

1 INTRODUCTION 51

• 1.1 OBJECTIVES OF THE STUDY 51
• 1.2 MARKET DEFINITION 51
• 1.3 OVERVIEW OF GLOBAL G-CSF / PEG-G-CSF MARKET 51
• 1.4 LIMITATIONS 53
• 1.5 MARKETS COVERED 53

2 MARKET SEGMENTATION 56

• 2.1 MARKETS COVERED 56
• 2.2 GEOGRAPHICAL SCOPE 57
• 2.3 YEARS CONSIDERED FOR THE STUDY 58
• 2.4 CURRENCY AND PRICING 58
• 2.5 DBMR TRIPOD DATA VALIDATION MODEL 59
• 2.6 MULTIVARIATE MODELLING 62
• 2.7 TYPE LIFELINE CURVE 62
• 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 63
• 2.9 DBMR MARKET POSITION GRID 64
• 2.10 MARKET END USER COVERAGE GRID 65
• 2.11 VENDOR SHARE ANALYSIS 66
• 2.12 SECONDARY SOURCES 67
• 2.13 ASSUMPTIONS 67

3 EXECUTIVE SUMMARY 68

4 PREMIUM INSIGHTS 71

• 4.1 PESTEL ANALYSIS 74
• 4.2 PORTER'S FIVE FORCES 75
• 4.3 GLOBAL G-CSF/PEG-G-CSF MARKET: MERGERS AND ACQUISITION 76
• 4.4 GLOBAL G-CSF / PEG-G-CSF MARKET 77
• 4.5 STRATEGIES TO THE ENTER THE MARKET 77
  • 4.5.1 JOINT VENTURE (PARTNERSHIPS): 77
  • 4.5.2 ACQUISITION: 77
  • 4.5.3 LINE EXPANSION VIA COLLABORATION: 77
  • 4.5.4 PRODUCT APPROVAL: 78
  • 4.5.5 PRODUCT LAUNCH: 78
  • 4.5.6 GEOGRAPHIC EXPANSION: 78
  • 4.5.7 COST LEADERSHIP: 79
  • 4.5.8 PRODUCT DEVELOPMENT: 79
• 4.6 GLOBAL G-CSF / PEG-G-CSF MARKET, INDUSTRY INSIGHTS 80
  • 4.6.1 PATENT ANALYSIS 80
  • 4.6.2 DRUG TREATMENT RATE BY MATURED MARKETS 81
  • 4.6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 81
  • 4.6.4 THERAPEUTIC ASSESSMENT 81
  • 4.6.5 KEY PRICING STRATEGIES 82
  • 4.6.6 KEY PATIENT ENROLLMENT STRATEGIES 82
  • 4.6.7 CONCLUSION 82
• 4.7 PIPELINE ANALYSIS FOR GLOBAL G-CSF / PEG-G-CSF MARKET 83

5 EPIDEMIOLOGY 84

6 GLOBAL G-CSF / PEG-G-CSF MARKET: REGULATIONS 87

7 MARKET OVERVIEW 90

• 7.1 DRIVERS 92
  • 7.1.1 GROWING INCIDENCES OF BLOOD CANCERS AND CANCER DISEASES 92
  • 7.1.2 RISING INCIDENCES OF AUTOIMMUNE DISORDERS 93
  • 7.1.3 INCREASING CASES OF FEBRILE NEUTROPENIA 94
  • 7.1.4 INCREASING AWARENESS ABOUT FILGRASTIM AND PEGFILGRASTIM 95
• 7.2 RESTRAIN 96
  • 7.2.1 STRINGENT GOVERNMENTAL REGULATIONS 96
  • 7.2.2 AVAILABILITY OF ALTERNATIVES FOR THE CHEMOTHERAPY 97
• 7.3 OPPORTUNITIES 98
  • 7.3.1 THE USE OF BIOSIMILARS HELPS REDUCE HEALTHCARE COSTS FOR PATIENTS 98
  • 7.3.2 COST-EFFECTIVENESS AND PATENT EXPIRY OF BIOLOGICAL PRODUCTS 98
• 7.4 CHALLENGES 99
  • 7.4.1 THE HIGH COST ASSOCIATED WITH BRANDED BIOLOGICS AND IMPROVED CHEMOTHERAPY 99
  • 7.4.2 THE MULTIPLE SIDE EFFECTS OF G-CSF 99

8 GLOBAL G-CSF/ PEG-G-CSF MARKET, BY INDICATION 100

• 8.1 OVERVIEW 101
• 8.2 NEUTROPENIA 105
  • 8.2.1 CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA (MYELOSUPPRESSIVE CHEMOTHERAPY TREATMENT) 106
  • 8.2.2 SEVERE CHRONIC NEUTROPENIA 106
  • 8.2.3 RADIOTHERAPY INDUCED NEUTROPENIA 106
  • 8.2.4 NEUTROPENIA IN HIV PATIENTS 106
  • 8.2.5 CLOZAPINE INDUCED NEUTROPENIA 106
  • 8.2.6 NEUTROPENIA IN HEPATITIS C PATIENTS 106
  • 8.2.7 CONGENITAL NEUTROPENIA 106
• 8.3 ONCOLOGY 107
  • 8.3.1 ACUTE MYELOID LEUKEMIA RECEIVING CONSOLIDATION CHEMOTHERAPY 107
  • 8.3.2 OTHERS 108
• 8.4 CHRONIC AND AUTO IMMUNE DISEASES 108
• 8.5 BLOOD DISORDERS 108
• 8.6 GROWTH HORMONE DEFICIENCY 109
• 8.7 OTHERS 110

9 GLOBAL G-CSF/ PEG-G-CSF MARKET, BY DOSAGE 111

• 9.1 OVERVIEW 112
• 9.2 MONO 115
• 9.3 COMBINATION 116

10 GLOBAL G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION 117

• 10.1 OVERVIEW 118
• 10.2 SUBCUTANEOUS 121
• 10.3 INTRAVENOUS 122

11 GLOBAL G-CSF/ PEG-G-CSF MARKET, BY PACKAGING 123

• 11.1 OVERVIEW 124
• 11.2 PRE FILLED SYRINGES 127
• 11.3 SINGLE USE VIALS 128

12 GLOBAL G-CSF/ PEG-G-CSF MARKET, BY END USER 129

• 12.1 OVERVIEW 130
• 12.2 HOSPITALS AND CLINICS 133
• 12.3 RESEARCH & ACADEMIC INSTITUTES 133
• 12.4 AMBULATORY SURGICAL CENTERS 134
• 12.5 OTHERS 135

13 GLOBAL G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL 136

• 13.1 OVERVIEW 137
• 13.2 HOSPITALS PHARMACY 140
• 13.3 RETAIL PHARMACY 140
• 13.4 ONLINE PHARMACY 141
• 13.5 OTHERS 142

14 GLOBAL G-CSF/PEG-G-CSF MARKET, BY REGION 143

• 14.1 OVERVIEW 144
• 14.2 EUROPE 149
  • 14.2.1 RUSSIA 156
  • 14.2.2 TURKEY 164
• 14.3 ASIA-PACIFIC 175
  • 14.3.1 CHINA 182
  • 14.3.2 INDIA 190
  • 14.3.3 INDONESIA 200
  • 14.3.4 THAILAND 208
  • 14.3.5 VIETNAM 215
  • 14.3.6 SINGAPORE 222
  • 14.3.7 PHILIPPINES 230
  • 14.3.8 MALAYSIA 237
• 14.4 LATIN AMERICA 243
  • 14.4.1 MEXICO 249
  • 14.4.2 COLUMBIA 257
  • 14.4.3 BRAZIL 264
  • 14.4.4 ARGENTINA 272
  • 14.4.5 CHILE 282
  • 14.4.6 PERU 289
  • 14.4.7 ECUADOR 296
• 14.5 MIDDLE EAST AND AFRICA 304
  • 14.5.1 SOUTH AFRICA 310
  • 14.5.2 SAUDI ARABIA 318
  • 14.5.3 EGYPT 325
  • 14.5.4 ISRAEL 333
  • 14.5.5 UAE 340
  • 14.5.6 KUWAIT 346
  • 14.5.7 OMAN 353

15 GLOBAL G-CSF / PEG-G-CSF MARKET, COMPANY LANDSCAPE 360

• 15.1 COMPANY SHARE ANALYSIS: GLOBAL 360
• 15.2 COMPANY SHARE ANALYSIS: EUROPE 361
• 15.3 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 362
• 15.4 COMPANY SHARE ANALYSIS: LATAM 363

16 SWOT ANALYSIS 364

17 COMPANY PROFILE 365

• 17.1 PFIZER INC. 365
  • 17.1.1 COMPANY SNAPSHOT 365
  • 17.1.2 REVENUE ANALYSIS 366
  • 17.1.3 COMPANY SHARE ANALYSIS 366
  • 17.1.4 PRODUCT PORTFOLIO 367
  • 17.1.5 RECENT DEVELOPMENTS 367
• 17.2 VIATRIS INC. 368
  • 17.2.1 COMPANY SNAPSHOT 368
  • 17.2.2 REVENUE ANALYSIS 368
  • 17.2.3 COMPANY SHARE ANALYSIS 369
  • 17.2.4 PRODUCT PORTFOLIO 369
  • 17.2.5 RECENT DEVELOPMENT 369
• 17.3 AMGEN INC. 370
  • 17.3.1 COMPANY SNAPSHOT 370
  • 17.3.2 REVENUE ANALYSIS 370
  • 17.3.3 COMPANY SHARE ANALYSIS 371
  • 17.3.4 PRODUCT PORTFOLIO 371
  • 17.3.5 RECENT DEVELOPMENTS 371
• 17.4 STADA ARZENEIMITTEL AG 373
  • 17.4.1 COMPANY SNAPSHOT 373
  • 17.4.2 COMPANY SHARE ANALYSIS 373
  • 17.4.3 PRODUCT PORTFOLIO 374
  • 17.4.4 RECENT DEVELOPMENT 374
• 17.5 TEVA PHARMACEUTICAL INDUSTRIES LTD. 375
  • 17.5.1 COMPANY SNAPSHOT 375
  • 17.5.2 REVENUE ANALYSIS 375
  • 17.5.3 COMPANY SHARE ANALYSIS 376
  • 17.5.4 PRODUCT PORTFOLIO 376
  • 17.5.5 RECENT DEVELOPMENTS 376
• 17.6 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. 377
  • 17.6.1 COMPANY SNAPSHOT 377
  • 17.6.2 PRODUCT PORTFOLIO 377
  • 17.6.3 RECENT DEVELOPMENTS 377
• 17.7 ACCORD HEALTHCARE 378
  • 17.7.1 COMPANY SNAPSHOT 378
  • 17.7.2 PRODUCT PORTFOLIO 378
  • 17.7.3 RECENT DEVELOPMENTS 378
• 17.8 AMNEAL PHARMACEUTICALS LLC. 379
  • 17.8.1 COMPANY SNAPSHOT 379
  • 17.8.2 REVENUE ANALYSIS 379
  • 17.8.3 PRODUCT PORTFOLIO 380
  • 17.8.4 RECENT DEVELOPMENTS 380
• 17.9 APOTEX INC. 381
  • 17.9.1 COMPANY SNAPSHOT 381
  • 17.9.2 PRODUCT PORTFOLIO 381
  • 17.9.3 RECENT DEVELOPMENT 381
• 17.10 BIOCON 382
  • 17.10.1 COMPANY SNAPSHOT 382
  • 17.10.2 REVENUE ANALYSIS 382
  • 17.10.3 PRODUCT PORTFOLIO 383
  • 17.10.4 RECENT DEVELOPMENT 383
• 17.11 BIO SIDUS 384
  • 17.11.1 COMPANY SNAPSHOT 384
  • 17.11.2 PRODUCT PORTFOLIO 384
  • 17.11.3 RECENT DEVELOPMENTS 384
• 17.12 CADILA PHARMACEUTICALS 385
  • 17.12.1 COMPANY SNAPSHOT 385
  • 17.12.2 PRODUCT PORTFOLIO 385
  • 17.12.3 RECENT DEVELOPMENTS 385
• 17.13 COHERUS BIOSCIENCES 386
  • 17.13.1 COMPANY SNAPSHOT 386
  • 17.13.2 REVENUE ANALYSIS 386
  • 17.13.3 PRODUCT PORTFOLIO 387
  • 17.13.4 RECENT DEVELOPMENT 387
• 17.14 DR. REDDY'S LABORATORIES LTD 388
  • 17.14.1 COMPANY SNAPSHOT 388
  • 17.14.2 REVENUE ANALYSIS 388
  • 17.14.3 PRODUCT PORTFOLIO 389
  • 17.14.4 RECENT DEVELOPMENTS 389
• 17.15 FRESENIUS KABI AG 390
  • 17.15.1 COMPANY SNAPSHOT 390
  • 17.15.2 PRODUCT PORTFOLIO 390
  • 17.15.3 RECENT DEVELOPMENT 390
• 17.16 GENNOVA BIOPHARMACEUTICALS LIMITED 391
  • 17.16.1 COMPANY SNAPSHOT 391
  • 17.16.2 PRODUCT PORTFOLIO 391
  • 17.16.3 RECENT DEVELOPMENTS 391
• 17.17 HANGZHOU JIUYUAN GENE ENGINEERING CO., LTD. 392
  • 17.17.1 COMPANY SNAPSHOT 392
  • 17.17.2 PRODUCT PORTFOLIO 392
  • 17.17.3 RECENT DEVELOPMENTS 392
• 17.18 INTAS PHARMACEUTICALS LTD. 393
  • 17.18.1 COMPANY SNAPSHOT 393
  • 17.18.2 PRODUCT PORTFOLIO 393
  • 17.18.3 RECENT DEVELOPMENT 393
• 17.19 KASHIV BIOSCIENCES, LLC. 394
  • 17.19.1 COMPANY SNAPSHOT 394
  • 17.19.2 PRODUCT PORTFOLIO 394
  • 17.19.3 RECENT DEVELOPMENT 394
• 17.20 KYOWA KIRIN CO., LTD. 395
  • 17.20.1 COMPANY SNAPSHOT 395
  • 17.20.2 REVENUE ANALYSIS 395
  • 17.20.3 PRODUCT PORTFOLIO 396
  • 17.20.4 RECENT DEVELOPMENT 396
• 17.21 LUPIN 397
  • 17.21.1 COMPANY SNAPSHOT 397
  • 17.21.2 REVENUE ANALYSIS 397
  • 17.21.3 PRODUCT PORTFOLIO 398
  • 17.21.4 RECENT DEVELOPMENT 398
• 17.22 MUNDIPHARMA INTERNATIONAL. 399
  • 17.22.1 COMPANY SNAPSHOT 399
  • 17.22.2 PRODUCT PORTFOLIO 399
  • 17.22.3 RECENT DEVELOPMENT 399
• 17.23 NAPP PHARMACEUTICALS LIMITED 400
  • 17.23.1 COMPANY SNAPSHOT 400
  • 17.23.2 PRODUCT PORTFOLIO 400
  • 17.23.3 RECENT DEVELOPMENT 400
• 17.24 RELIANCE LIFE SCIENCES 401
  • 17.24.1 COMPANY SNAPSHOT 401
  • 17.24.2 PRODUCT PORTFOLIO 401
  • 17.24.3 RECENT DEVELOPMENTS 401